FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115258511> ?p ?o ?g. }

• W2115258511 endingPage "76" @default.
• W2115258511 startingPage "69" @default.
• W2115258511 abstract "Background Ciclesonide is a corticosteroid in development for allergic rhinitis that has been shown to be safe and effective in seasonal allergic rhinitis and perennial allergic rhinitis (PAR) trials of up to 6 weeks in duration. However, the long-term safety and efficacy of ciclesonide are unknown. Objective To demonstrate the long-term safety of intranasal ciclesonide, 200 μg once daily, in patients with PAR. Methods Patients (≥12 years old) with a 2-year or longer history of PAR were randomized in a double-blind fashion to receive ciclesonide, 200 μg, or placebo once daily in the morning for up to 52 weeks. Spontaneous and elicited adverse events were monitored throughout the study. Ear, nose, and throat examinations were performed to evaluate local tolerability. Additionally, 24-hour urinary free cortisol level, morning plasma cortisol level, intraocular pressure, and lens opacification were monitored to evaluate the systemic safety of intranasal ciclesonide. Ciclesonide efficacy was determined by measuring 24-hour reflective total nasal symptom scores. Results No clinically relevant differences were observed between the ciclesonide and placebo groups in adverse events, ear, nose, and throat examinations, or 24-hour urinary free or morning plasma cortisol levels. Similarly, no clinically relevant differences were found between treatment groups in intraocular pressure, visual acuity, or lens opacification. With regard to efficacy, ciclesonide achieved a significantly greater reduction in 24-hour reflective total nasal symptom score compared with placebo over more than 52 weeks (P < .001). Conclusion In this study, intranasal ciclesonide, 200 μg once daily, was safe and effective for the long-term treatment of PAR, with no evidence of tachyphylaxis. Ciclesonide is a corticosteroid in development for allergic rhinitis that has been shown to be safe and effective in seasonal allergic rhinitis and perennial allergic rhinitis (PAR) trials of up to 6 weeks in duration. However, the long-term safety and efficacy of ciclesonide are unknown. To demonstrate the long-term safety of intranasal ciclesonide, 200 μg once daily, in patients with PAR. Patients (≥12 years old) with a 2-year or longer history of PAR were randomized in a double-blind fashion to receive ciclesonide, 200 μg, or placebo once daily in the morning for up to 52 weeks. Spontaneous and elicited adverse events were monitored throughout the study. Ear, nose, and throat examinations were performed to evaluate local tolerability. Additionally, 24-hour urinary free cortisol level, morning plasma cortisol level, intraocular pressure, and lens opacification were monitored to evaluate the systemic safety of intranasal ciclesonide. Ciclesonide efficacy was determined by measuring 24-hour reflective total nasal symptom scores. No clinically relevant differences were observed between the ciclesonide and placebo groups in adverse events, ear, nose, and throat examinations, or 24-hour urinary free or morning plasma cortisol levels. Similarly, no clinically relevant differences were found between treatment groups in intraocular pressure, visual acuity, or lens opacification. With regard to efficacy, ciclesonide achieved a significantly greater reduction in 24-hour reflective total nasal symptom score compared with placebo over more than 52 weeks (P < .001). In this study, intranasal ciclesonide, 200 μg once daily, was safe and effective for the long-term treatment of PAR, with no evidence of tachyphylaxis." @default.
• W2115258511 created "2016-06-24" @default.
• W2115258511 creator A5005080145 @default.
• W2115258511 creator A5038482736 @default.
• W2115258511 creator A5059729118 @default.
• W2115258511 creator A5073836666 @default.
• W2115258511 creator A5075475431 @default.
• W2115258511 creator A5076385418 @default.
• W2115258511 creator A5076701544 @default.
• W2115258511 date "2007-07-01" @default.
• W2115258511 modified "2023-10-14" @default.
• W2115258511 title "Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis" @default.
• W2115258511 cites W1973102856 @default.
• W2115258511 cites W1973755752 @default.
• W2115258511 cites W1977311048 @default.
• W2115258511 cites W1984622531 @default.
• W2115258511 cites W2013640794 @default.
• W2115258511 cites W2019921656 @default.
• W2115258511 cites W2024349915 @default.
• W2115258511 cites W2033155597 @default.
• W2115258511 cites W2060101668 @default.
• W2115258511 cites W2073100929 @default.
• W2115258511 cites W2094281842 @default.
• W2115258511 cites W2096210343 @default.
• W2115258511 cites W2099838434 @default.
• W2115258511 cites W2102926338 @default.
• W2115258511 cites W2155701010 @default.
• W2115258511 cites W2163761361 @default.
• W2115258511 cites W2465424424 @default.
• W2115258511 cites W3124794673 @default.
• W2115258511 cites W4321428285 @default.
• W2115258511 cites W4377862865 @default.
• W2115258511 doi "https://doi.org/10.1016/s1081-1206(10)60624-2" @default.
• W2115258511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17650833" @default.
• W2115258511 hasPublicationYear "2007" @default.
• W2115258511 type Work @default.
• W2115258511 sameAs 2115258511 @default.
• W2115258511 citedByCount "41" @default.
• W2115258511 countsByYear W21152585112012 @default.
• W2115258511 countsByYear W21152585112013 @default.
• W2115258511 countsByYear W21152585112014 @default.
• W2115258511 countsByYear W21152585112015 @default.
• W2115258511 countsByYear W21152585112018 @default.
• W2115258511 countsByYear W21152585112019 @default.
• W2115258511 countsByYear W21152585112020 @default.
• W2115258511 countsByYear W21152585112021 @default.
• W2115258511 countsByYear W21152585112022 @default.
• W2115258511 countsByYear W21152585112023 @default.
• W2115258511 crossrefType "journal-article" @default.
• W2115258511 hasAuthorship W2115258511A5005080145 @default.
• W2115258511 hasAuthorship W2115258511A5038482736 @default.
• W2115258511 hasAuthorship W2115258511A5059729118 @default.
• W2115258511 hasAuthorship W2115258511A5073836666 @default.
• W2115258511 hasAuthorship W2115258511A5075475431 @default.
• W2115258511 hasAuthorship W2115258511A5076385418 @default.
• W2115258511 hasAuthorship W2115258511A5076701544 @default.
• W2115258511 hasConcept C126322002 @default.
• W2115258511 hasConcept C141071460 @default.
• W2115258511 hasConcept C142724271 @default.
• W2115258511 hasConcept C19720800 @default.
• W2115258511 hasConcept C197934379 @default.
• W2115258511 hasConcept C204787440 @default.
• W2115258511 hasConcept C27081682 @default.
• W2115258511 hasConcept C2776042228 @default.
• W2115258511 hasConcept C2776804153 @default.
• W2115258511 hasConcept C2777588912 @default.
• W2115258511 hasConcept C2778311950 @default.
• W2115258511 hasConcept C2778375690 @default.
• W2115258511 hasConcept C2780973058 @default.
• W2115258511 hasConcept C2991922776 @default.
• W2115258511 hasConcept C42219234 @default.
• W2115258511 hasConcept C71924100 @default.
• W2115258511 hasConcept C85663871 @default.
• W2115258511 hasConcept C98274493 @default.
• W2115258511 hasConceptScore W2115258511C126322002 @default.
• W2115258511 hasConceptScore W2115258511C141071460 @default.
• W2115258511 hasConceptScore W2115258511C142724271 @default.
• W2115258511 hasConceptScore W2115258511C19720800 @default.
• W2115258511 hasConceptScore W2115258511C197934379 @default.
• W2115258511 hasConceptScore W2115258511C204787440 @default.
• W2115258511 hasConceptScore W2115258511C27081682 @default.
• W2115258511 hasConceptScore W2115258511C2776042228 @default.
• W2115258511 hasConceptScore W2115258511C2776804153 @default.
• W2115258511 hasConceptScore W2115258511C2777588912 @default.
• W2115258511 hasConceptScore W2115258511C2778311950 @default.
• W2115258511 hasConceptScore W2115258511C2778375690 @default.
• W2115258511 hasConceptScore W2115258511C2780973058 @default.
• W2115258511 hasConceptScore W2115258511C2991922776 @default.
• W2115258511 hasConceptScore W2115258511C42219234 @default.
• W2115258511 hasConceptScore W2115258511C71924100 @default.
• W2115258511 hasConceptScore W2115258511C85663871 @default.
• W2115258511 hasConceptScore W2115258511C98274493 @default.
• W2115258511 hasIssue "1" @default.
• W2115258511 hasLocation W21152585111 @default.
• W2115258511 hasLocation W21152585112 @default.
• W2115258511 hasOpenAccess W2115258511 @default.
• W2115258511 hasPrimaryLocation W21152585111 @default.
• W2115258511 hasRelatedWork W114379940 @default.

• next